Emergence of Extended-Spectrum Beta-Lactamase and Carbapenemase Producing Gram Negative Non-Fermenters at Selected Hospitals of Northeast Ethiopia: A Prospective Cross-Sectional Study

References

• Bitew A. High prevalence of multi-drug resistance and extended spectrum beta lactamase production in non-fermenting gram-negative bacilli in Ethiopia. Infect Dis. 2019;12:1178633719884951.
   Google Scholar
• World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities. World Health Organization; 2017.
   Google Scholar
• Shanthi M, Sekar U. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes. J Assoc Physicians India. 2009;57(636):8–40, 45.
   Google Scholar
• Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:1–8. doi:10.1155/2016/2475067
   Web of Science ®Google Scholar
• Ding C, Yang Z, Wang J, et al. Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: a systematic review and meta-analysis. Int J Infect Dis. 2016;49:119–128. doi:10.1016/j.ijid.2016.06.014
   PubMed Web of Science ®Google Scholar
• Lee C-R, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55. doi:10.3389/fcimb.2017.00055
   PubMed Web of Science ®Google Scholar
• Koirala A, Agrahari G, Dahal N, Ghimire P, Rijal K. ESBL and MBL mediated resistance in clinical isolates of nonfermentating Gram negative bacilli (NFGNB) in Nepal. J Microb Antimicrob Agents. 2017;3(1):18–24.
   Google Scholar
• Kanafani Z, Kanj S. Acinetobacter infection: Treatment and prevention; 2020.
   Google Scholar
• Lee C-S, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother. 2014;46(3):149–164. doi:10.3947/ic.2014.46.3.149
   PubMedGoogle Scholar
• Lemos E, de La Hoz F, Einarson T, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• Riedel S, Morse SA, Mietzner TA, Miller S. Jawetz Melnick & Adelbergs Medical Microbiology 28 E. McGraw Hill Professional; 2019.
   Google Scholar
• Ali HM, Salem MZ, El-Shikh MS, Megeed AA, Alogaibi YA, Talea IA. Investigation of the virulence factors and molecular characterization of the clonal relations of multidrug-resistant Acinetobacter baumannii isolates. J AOAC Int. 2017;100(1):152–158. doi:10.5740/jaoacint.16-0139
   PubMed Web of Science ®Google Scholar
• Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.12125
   PubMed Web of Science ®Google Scholar
• Aliramezani A, Soleimani M, Fard RMN, Nojoomi F. Virulence determinants and biofilm formation of Acinetobacter baumannii isolated from hospitalized patients. Germs. 2019;9(3):148–153. doi:10.18683/germs.2019.1171
   PubMedGoogle Scholar
• Taylor PK, Yeung AT, Hancock RE. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol. 2014;191:121–130. doi:10.1016/j.jbiotec.2014.09.003
   PubMed Web of Science ®Google Scholar
• Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67(3):159–173. doi:10.1111/2049-632X.12033
   PubMed Web of Science ®Google Scholar
• Control CfD, Prevention. Antibiotic Resistance Threats in the United States, 2019. US Department of Health and Human Services, Centres for Disease Control; 2019.
   Google Scholar
• Mathlouthi N, Areig Z, Al Bayssari C, et al. Emergence of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates collected from some Libyan hospitals. Microbial Drug Res. 2015;21(3):335–341. doi:10.1089/mdr.2014.0235
   PubMed Web of Science ®Google Scholar
• Llaca-Díaz JM, Mendoza-Olazarán S, Camacho-Ortiz A, Flores S, Garza-González E. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy. 2012;58(6):475–481. doi:10.1159/000346352
   PubMed Web of Science ®Google Scholar
• Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5:1–15. doi:10.1186/s13613-015-0061-0
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi:10.1128/AAC.00296-11
   PubMed Web of Science ®Google Scholar
• Mehrad B, Clark NM, Zhanel GG, Lynch JP III. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 2015;147(5):1413–1421. doi:10.1378/chest.14-2171
   PubMed Web of Science ®Google Scholar
• Wayne. Performance standards for antimicrobial disk susceptibility tests. PA: (CLSI) CaLSI; 2020).
   Google Scholar
• Control CfD, Prevention. Antibiotic resistance threats report; 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threatshtml. Accessed July 07, 2023.
   Google Scholar
• Begum N, Shamsuzzaman S. Emergence of carbapenemase-producing urinary isolates at a tertiary care hospital in Dhaka, Bangladesh. Tzu Chi MedJ. 2016;28(3):94–98. doi:10.1016/j.tcmj.2016.04.005
   Google Scholar
• Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Inf Dis. 2017;2017:1.
   Google Scholar
• Gashaw M, Berhane M, Bekele S, et al. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infect Control. 2018;7:1–8. doi:10.1186/s13756-018-0431-0
   PubMed Web of Science ®Google Scholar
• Kateete DP, Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago hospital in Kampala, Uganda (2007–2009). Springerplus. 2016;5:1–11. doi:10.1186/s40064-016-2986-7
   PubMedGoogle Scholar
• Ramette A, Kronenberg A, Burnens A, et al. Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland. BMC Infect Dis. 2018;18(1):159. doi:10.1186/s12879-018-3061-5
   PubMedGoogle Scholar
• Kindu M, Derseh L, Gelaw B, Moges F. Carbapenemase-producing non-glucose-fermenting gram-negative Bacilli in Africa, Pseudomonas aeruginosa and Acinetobacter baumannii: a systematic review and meta-analysis. Int J Microbiol. 2020;2020:9461901. doi:10.1155/2020/9461901
   PubMed Web of Science ®Google Scholar
• Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12(1):1–8. doi:10.1186/1472-6963-12-122
   PubMedGoogle Scholar
• Subramaniyan SJ, Sundaram JM. Occurrence of bla -genes encoding carbapenem‑ resistant Pseudomonas aeruginosa and Acinetobacter baumannii from Intensive Care Unit in a tertiary care hospital. J Lab Physicians. 2018;10(2):208–213. doi:10.4103/JLP.JLP_108_17
   PubMed Web of Science ®Google Scholar
• Cheesbrough M. District laboratory practice in tropical countries. IJMS. 2006;2(7.16):137.
   Google Scholar
• Elham B, Fawzia AJ. Colistin resistance in Acinetobacter baumannii isolated from critically ill patients: clinical characteristics, antimicrobial susceptibility and outcome. Afr Health Sci. 2019;19(3):2400–2406. doi:10.4314/ahs.v19i3.13
   PubMed Web of Science ®Google Scholar
• Gopal MA. Isolation and identification of Pseudomonas aeruginosa FROM UROPATHOGENS. University of Yangon Res J. 2020;7:11.
   Google Scholar
• Desta M, Amha H, Anteneh Bishaw K, et al. Prevalence and predictors of uterine rupture among Ethiopian women: a systematic review and meta-analysis. PLoS One. 2020;15(11):e0240675. doi:10.1371/journal.pone.0240675
   PubMed Web of Science ®Google Scholar
• Randrianirina F, Vaillant L, Ramarokoto CE, et al. Antimicrobial resistance in pathogens causing nosocomial infections in surgery and intensive care units of two hospitals in Antananarivo, Madagascar. J Infect Dev Ctries. 2010;4(02):074–82. doi:10.3855/jidc.454
   PubMedGoogle Scholar
• Kaur A, Singh S. Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) Producing Pseudomonas aeruginosa and Acinetobacter baumannii Isolated from Various Clinical Samples. J Pathog. 2018;2018:1–7. doi:10.1155/2018/6845985
   Web of Science ®Google Scholar
• Wasihun AG, Wlekidan LN, Gebremariam SA, et al. Bacteriological profile and antimicrobial susceptibility patterns of blood culture isolates among febrile patients in Mekelle Hospital, Northern Ethiopia. Springerplus. 2015;4(1):1–7. doi:10.1186/2193-1801-4-1
   PubMedGoogle Scholar
• Ampaire L, Nduhura E, Wewedru I. Phenotypic prevalence of extended spectrum beta-lactamases among Enterobacteriaceae isolated at mulago national referral hospital: Uganda. BMC Res Notes. 2017;10(1):1–4. doi:10.1186/s13104-017-2786-3
   PubMedGoogle Scholar
• Moges F, Eshetie S, Abebe W, et al. High prevalence of extended-spectrum beta-lactamase-producing Gram-negative pathogens from patients attending Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Amhara region. PLoS One. 2019;14(4):e0215177. doi:10.1371/journal.pone.0215177
   PubMed Web of Science ®Google Scholar
• El-Baky RM A, Farhan SM, Ibrahim RA, Mahran KM, Hetta HF. Antimicrobial resistance pattern and molecular epidemiology of ESBL and MBL producing Acinetobacter baumannii isolated from hospitals in Minia, Egypt. Alexandria J Med. 2020;56(1):4–13. doi:10.1080/20905068.2019.1707350
   Web of Science ®Google Scholar
• Goel V, Hogade SA, Karadesai S. Prevalence of extended-spectrum beta-lactamases, AmpC beta-lactamase, and metallo-beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii in an intensive care unit in a tertiary care hospital. J Sci Soc. 2013;40(1):28. doi:10.4103/0974-5009.109691
   Google Scholar
• Ntirenganya C, Manzi O, Muvunyi CM, Ogbuagu O. High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda. Am J Trop Med Hyg. 2015;92(4):865. doi:10.4269/ajtmh.14-0607
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay M, Chakraborty B, Kumar S, et al. A study on burden of carbapenem-resistant pseudomonas aeruginosa and Acinetobacter baumannii infections in a tertiary care hospital of eastern India; 2019.
   Google Scholar
• Labarca JA, Salles MJC, Seas C, Guzmán-Blanco M. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol. 2016;42(2):276–292. doi:10.3109/1040841X.2014.940494
   PubMed Web of Science ®Google Scholar
• Solomon FB, Wadilo F, Tufa EG, Mitiku M. Extended spectrum and metalo beta-lactamase producing airborne Pseudomonas aeruginosa and Acinetobacter baumannii in restricted settings of a referral hospital: a neglected condition. Antimicrob Resist Infect Control. 2017;6:1–7. doi:10.1186/s13756-017-0266-0
   Web of Science ®Google Scholar
• Kuntaman K, Shigemura K, Osawa K, et al. Occurrence and characterization of carbapenem‐resistant Gram‐negative bacilli: a collaborative study of antibiotic‐resistant bacteria between Indonesia and Japan. Int J Urol. 2018;25(11):966–972. doi:10.1111/iju.13787
   PubMed Web of Science ®Google Scholar
• Defaee S, Farasatinasab M, Makani MJ, Rahimipour H, Alinia P, Defaee S. Prevalence of gram negative infections by Acinetobacter and pseudomonas severely resistant to antibiotic susceptibility based on minimum growth inhibitor concentration. J Pharmaceut Res Inter. 2019;29(3):1–6. doi:10.9734/jpri/2019/v29i330235
   Web of Science ®Google Scholar
• Motbainor H, Bereded F, Mulu W. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20:1–11. doi:10.1186/s12879-020-4811-8
   Web of Science ®Google Scholar
• Ibrahim ME. Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. Ann Clin Microbiol Antimicrob. 2019;18(1):1. doi:10.1186/s12941-018-0301-x
   PubMed Web of Science ®Google Scholar
• Huang H, Chen B, Liu G, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infect Dis. 2018;18:1–6. doi:10.1186/s12879-017-2932-5
   PubMed Web of Science ®Google Scholar